Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Drug Profile

Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Alternative Names: GalNAc-siRNA - Silence Therapeutics; ICS-283; Research programme: RNAi-based therapeutics -Intradigm/Qiagen

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Intradigm Corporation
  • Developer Intradigm Corporation; OPKO Health; Silence Therapeutics
  • Class RNA; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified
  • Discontinued Age-related macular degeneration; Cancer; Coronavirus infections; Diabetic retinopathy

Most Recent Events

  • 14 Oct 2016 Discontinued - Preclinical for Age-related macular degeneration in USA (IV)
  • 14 Oct 2016 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
  • 14 Oct 2016 Discontinued - Preclinical for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top